CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
58.78
+2.28 (4.04%)
At close: Mar 9, 2026, 4:00 PM EDT
56.53
-2.25 (-3.83%)
After-hours: Mar 9, 2026, 7:58 PM EDT
CRISPR Therapeutics AG Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 347.56 | 298.26 | 389.48 | 211.89 | 923.03 | Upgrade
|
| Short-Term Investments | 1,628 | 1,606 | 1,304 | 1,603 | 1,456 | Upgrade
|
| Cash & Short-Term Investments | 1,976 | 1,904 | 1,694 | 1,815 | 2,379 | Upgrade
|
| Cash Growth | 3.78% | 12.41% | -6.70% | -23.70% | 40.75% | Upgrade
|
| Accounts Receivable | - | 25 | 200 | - | 0.31 | Upgrade
|
| Other Receivables | - | - | 6.5 | 11.2 | 8.4 | Upgrade
|
| Receivables | - | 25 | 206.5 | 11.2 | 8.71 | Upgrade
|
| Prepaid Expenses | 5.95 | 8.31 | 7.89 | 26.01 | 29.68 | Upgrade
|
| Restricted Cash | 3.89 | - | - | 0.5 | - | Upgrade
|
| Total Current Assets | 1,986 | 1,937 | 1,908 | 1,853 | 2,418 | Upgrade
|
| Property, Plant & Equipment | 247.58 | 277.55 | 305.94 | 320.56 | 312.04 | Upgrade
|
| Long-Term Investments | 22.6 | 12.9 | 1.97 | 53.13 | - | Upgrade
|
| Other Intangible Assets | - | - | 0.02 | 0.07 | 0.13 | Upgrade
|
| Other Long-Term Assets | 9.4 | 14.45 | 13.57 | 16.28 | 22.2 | Upgrade
|
| Total Assets | 2,265 | 2,242 | 2,230 | 2,243 | 2,752 | Upgrade
|
| Accounts Payable | 11.14 | 14.71 | 38.15 | 27.43 | 14.82 | Upgrade
|
| Accrued Expenses | 34.46 | 39.56 | 40.67 | 61.33 | 77.77 | Upgrade
|
| Current Portion of Leases | 18.58 | 17.29 | 15.63 | 15.84 | 12.16 | Upgrade
|
| Current Income Taxes Payable | 1.11 | 0.45 | 0.44 | 0.14 | 0.72 | Upgrade
|
| Current Unearned Revenue | 15.77 | 3.85 | 4.11 | - | 1.01 | Upgrade
|
| Other Current Liabilities | 68.06 | 11.93 | 9.81 | 16.38 | 13.4 | Upgrade
|
| Total Current Liabilities | 149.12 | 87.78 | 108.79 | 121.11 | 119.88 | Upgrade
|
| Long-Term Leases | 188.17 | 206.41 | 223.01 | 228.18 | 212.87 | Upgrade
|
| Long-Term Unearned Revenue | - | 12.32 | 14.01 | 12.32 | 12.32 | Upgrade
|
| Other Long-Term Liabilities | 6.14 | 3.44 | 0.96 | 5.97 | 7.34 | Upgrade
|
| Total Liabilities | 343.43 | 309.95 | 346.77 | 367.58 | 352.42 | Upgrade
|
| Common Stock | 3.09 | 2.7 | 2.5 | 2.44 | 2.39 | Upgrade
|
| Additional Paid-In Capital | 3,862 | 3,294 | 2,878 | 2,735 | 2,598 | Upgrade
|
| Retained Earnings | -1,948 | -1,366 | -999.7 | -846.09 | -195.92 | Upgrade
|
| Treasury Stock | -0.06 | -0.06 | -0.06 | -0.06 | -0.06 | Upgrade
|
| Comprehensive Income & Other | 4.82 | 1.84 | 1.91 | -15.65 | -5.07 | Upgrade
|
| Total Common Equity | 1,922 | 1,932 | 1,883 | 1,875 | 2,399 | Upgrade
|
| Shareholders' Equity | 1,922 | 1,932 | 1,883 | 1,875 | 2,399 | Upgrade
|
| Total Liabilities & Equity | 2,265 | 2,242 | 2,230 | 2,243 | 2,752 | Upgrade
|
| Total Debt | 206.75 | 223.69 | 238.63 | 244.02 | 225.03 | Upgrade
|
| Net Cash (Debt) | 1,769 | 1,680 | 1,457 | 1,624 | 2,154 | Upgrade
|
| Net Cash Growth | 5.29% | 15.31% | -10.30% | -24.59% | 32.24% | Upgrade
|
| Net Cash Per Share | 19.67 | 19.92 | 18.39 | 20.89 | 26.79 | Upgrade
|
| Filing Date Shares Outstanding | 95.99 | 85.77 | 80.28 | 78.65 | 77.07 | Upgrade
|
| Total Common Shares Outstanding | 95.89 | 85.74 | 80.04 | 78.51 | 76.99 | Upgrade
|
| Working Capital | 1,837 | 1,849 | 1,799 | 1,732 | 2,298 | Upgrade
|
| Book Value Per Share | 20.04 | 22.53 | 23.52 | 23.89 | 31.17 | Upgrade
|
| Tangible Book Value | 1,922 | 1,932 | 1,883 | 1,875 | 2,399 | Upgrade
|
| Tangible Book Value Per Share | 20.04 | 22.53 | 23.52 | 23.89 | 31.16 | Upgrade
|
| Machinery | 56.28 | 54.4 | 53.26 | 49.62 | 36.25 | Upgrade
|
| Construction In Progress | 3.96 | 6.12 | 8.86 | 6.16 | 52.4 | Upgrade
|
| Leasehold Improvements | 146.67 | 145.85 | 143.26 | 141.68 | 86.74 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.